Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03193372 · ClinicalTrials.gov registry record
A Study of Patient Concerns and Treatment Satisfaction in Patients Being Treated With Finacea Foam for Rosacea
A clinical trial, sponsored by LEO Pharma.
- Completed
- Registry status
- 2,200
- Enrollment target
NCT03193372: Completed study, sponsored by LEO Pharma.
NCT03193372 is a clinical trial that has completed, run by LEO Pharma. The registered enrollment target is 2,200 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03193372 has completed, sponsored by LEO Pharma.
- COMPLETED
- Registry status
- 2,200 participants
- Enrollment target
Study Summary
To survey rosacea patients about their concerns, treatment satisfaction, and quality of life associated with their Finacea Foam treatment
Primary Outcome
Collected patient demographics and characteristics are : * Year of birth * Gender * Insurance type
Interventions
- DRUG Azelaic Acid (Finacea Foam, BAY39-6251)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,200 participants |
| Start Date | 2017-07-20 |
| Est. Completion | 2017-11-15 |
What the finished NCT03193372 record still lists
NCT03193372 is an observational study that tracks outcomes without assigning an intervention. Its 2,200 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Azelaic Acid (Finacea Foam, BAY39-6251) is the first listed.
NCT03193372 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03193372 about?
NCT03193372 is a clinical study titled "A Study of Patient Concerns and Treatment Satisfaction in Patients Being Treated With Finacea Foam for Rosacea". To survey rosacea patients about their concerns, treatment satisfaction, and quality of life associated with their Finacea Foam treatment
What is the current status of trial NCT03193372?
This trial is currently completed. The enrollment target is 2,200 participants. The study started on 2017-07-20. Estimated completion is 2017-11-15.
What interventions are being tested in trial NCT03193372?
The interventions under investigation include: Azelaic Acid (Finacea Foam, BAY39-6251) (DRUG).
Who is sponsoring clinical trial NCT03193372?
This trial is sponsored by LEO Pharma, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05654207 · 2,200 participants · NA
WeCare: A System of Care for Black Youth
- NCT06144554 · 2,200 participants
Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
- NCT06526988 · 2,200 participants · NA
Implementation and Interaction of Clinician And Patient-facing Tools Aiming to Intensify Neurohormonal Medicines for Heart Failure
- NCT06682650 · 2,200 participants · NA
Implementation of a ColoRectal Cancer Screening Tool in US Primary Care Practices - Usual Quality Improvement (10 Clinics) vs Normalization Process Theory-Participatory Learning in Action (10 Clinics)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI